Biomolecules, Vol. 14, Pages 1328: The Biological Effect of Enriching the Plasma Content in Platelet-Rich Plasma: An In Vitro Study

Fecha de publicación: 18/10/2024
Fuente: Biomolecules - Revista científica (MDPI)
Biomolecules, Vol. 14, Pages 1328: The Biological Effect of Enriching the Plasma Content in Platelet-Rich Plasma: An In Vitro Study
Biomolecules doi: 10.3390/biom14101328
Authors:
Eduardo Anitua
Mar Zalduendo
Roberto Prado
María Troya
Roberto Tierno
María de la Fuente
Mohammad H. Alkhraisat

BACKGROUND: Platelet-rich plasma (PRP) formulations have become valuable therapeutic tools in regenerative medicine. In addition, these blood derivates have been successfully included in cell therapy as fetal bovine serum substitutes, due to the real need to avoid the risk of host immunologic reactions and the animal disease transmission associated with reagents from animal origin. However, the protocols for obtaining them should be optimized to improve their biological potential. METHODS: PRP-derived preparations with different concentrations of the platelet and plasma components were obtained from the blood of five donors by freeze-drying. Measurements of the pH, protein, and growth factor concentration were performed. Moreover, their biological effects on cell proliferation and migration and their angiogenic potential were assessed. RESULTS: An increased plasma component concentration resulted in an augmented quantity of the total protein content, a significative variation in the hepatocyte growth factor concentration, and an experimental but clinically irrelevant alteration of the pH value. No significant changes were induced in their potential to enhance proliferative and migratory responses in epithelial cells, with the latter being reduced for dermal fibroblasts. The endothelial cell capacity for tube formation was significatively reduced. CONCLUSIONS: An increased blood plasma content did not improve the biological potential of the formulations. However, they have emerged as a promising approach for regenerative therapies where neovascularization must be avoided.